Objective: To investigate the relationship between inflammatory [interleukin-6 (IL-6) and C-reactive protein (CRP)] and coagulation (D-dimer) biomarkers and cancer risk during HIV infection.
Design: A prospective cohort.
Methods: HIV-infected patients on continuous antiretroviral therapy (ART) in the control arms of three randomized trials (N = 5023) were included in an analysis of predictors of cancer (any type, infection-related or infection-unrelated). Hazard ratios for IL-6, CRP and D-dimer levels (log2-transformed) were calculated using Cox models stratified by trial and adjusted for demographics and CD4+ cell counts and adjusted also for all biomarkers simultaneously. To assess the possibility that biomarker levels were elevated at entry due to undiagnosed cancer, analyses were repeated excluding early cancer events (i.e. diagnosed during first 2 years of follow-up).
Results: During approximately 24 000 person-years of follow-up (PYFU), 172 patients developed cancer (70 infection-related; 102 infection-unrelated). The risk of developing cancer was associated with higher levels (per doubling) of IL-6 (hazard ratio 1.38, P < 0.001), CRP (hazard ratio 1.16, P = 0.001) and D-dimer (hazard ratio 1.17, P = 0.03). However, only IL-6 (hazard ratio 1.29, P = 0.003) remained associated with cancer risk when all biomarkers were considered simultaneously. Results for infection-related and infection-unrelated cancers were similar to results for any cancer. Hazard ratios excluding 69 early cancer events were 1.31 (P = 0.007), 1.14 (P = 0.02) and 1.07 (P = 0.49) for IL-6, CRP and D-dimer, respectively.
Conclusion: Activated inflammation and coagulation pathways are associated with increased cancer risk during HIV infection. This association was stronger for IL-6 and persisted after excluding early cancer. Trials of interventions may be warranted to assess whether cancer risk can be reduced by lowering IL-6 levels in HIV-positive individuals.
aDepartment of Infectious Diseases, Rigshospitalet and Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
bDivision of Research, Kaiser Permanente, Oakland, California
cDepartment of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA
dKirby Institute, University of New South Wales, Sydney, Australia
eFirst Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
fUCLA Center for Clinical AIDS Research and Education, David Geffen School of Medicine at UCLA, Los Angeles, USA
gDepartment of Infectious and Tropical Diseases, Vaccine and Immunotherapy Research Center, San Raffaele Scientific Institute Via Stamira d’Ancona, Milan, Italy
hResearch Department of Infection and Population Health, University College London (UCL), London, UK.
Correspondence to Álvaro H. Borges, Copenhagen HIV Programme, The Panum Institute/Building 21.1, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. E-mail: firstname.lastname@example.org
Received 22 November, 2012
Revised 23 January, 2013
Accepted 24 January, 2013
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).